The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to the interests of clinical research sites, announced a two-year partnership with Bristol-Myers Squibb.
The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to the interests of clinical research sites, announced a two-year partnership with Bristol-Myers Squibb, a leading global biopharmaceutical company. Bristol-Myers Squibb will participate as a Global Impact Partner (GIP), a relationship indicative of Bristol-Myers Squibb’s dedication to promoting greater site sustainability across the global clinical research landscape. Bristol-Myers Squibb will also host a Site Advocacy Group. As a GIP, Bristol-Myers Squibb will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council in the development and execution of strategic initiatives for SCRS.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.